FDA Disease Models Will Focus On Areas With Poor R&D Track Records
Executive Summary
FDA's disease state modeling efforts may focus on therapeutic areas which traditionally have suboptimal drug development, Office of Clinical Pharmacology & Biopharmaceutics Director Larry Lesko said